Israel’s BrainStorm Cell Therapeutics, which is developing an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating officer.
Kern, who has also been named chief medical officer, joins BrainStorm from Biogen, where he was senior vice president and head of worldwide medical. At Biogen he helped define the company’s therapeutic area and scientific strategies for Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy, Parkinson’s, neurodegeneration and hemophilia.
He was previously head of the neuroscience medical unit at Novartis and global medical director of personalized genetic health at Genzyme Corp.
BrainStorm is preparing to conduct a Phase 3 clinical trial for its NurOwn treatment at multiple sites in the United States and Israel. The company has said the advanced trial is expected to begin enrolling patients in the second quarter.
“I am confident that BrainStorm will become the world leader in adult stem cell therapies for neurodegenerative disorders,” Kern said.
By Tova Cohen
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.